News dal mondo
21
Apr
TGA clarifies therapeutic goods are unaffected by chemical production and import ban
TGA has clarified the impact of Australia’s industrial chemicals standards on medicines, medical devices, and biologicals. Responding to stakeholder queries, TGA said therapeutic goods are not affected by prohibitions imposed under the Industrial Chemicals Environmental Management Standard (IChEMS). The framework prohibits the import, manufacture, and use of specified chemicals in Australia. Certain PFAS chemicals, UV-328, and Dechlorane Plus are among the chemicals covered by IChEMS. TGA said IChEMS does not apply to chemicals used for therapeutic purposes. That limitation of the standard’s scope extends to the primary and secondary packaging of medicines and biologicals, as well as to the primary packaging, instructions for use, and spare parts of medical devices. The agency posted two statements about the exemption of medical devices from the PFAS ban last year. While TGA’s second statement clarified that medicines and biologicals are exempt from the ban, neither notice addressed chemicals other than PFAS. [RAPS]
12
Mag
Chimica: Bruxelles non rivedra' le norme REACH
Bruxelles non rivedra' le norme Reach, troppa incertezza per il settore La Commissione europea ha...
08
Mag
Farmaceutica, Gemmato: 'per Testo unico deadline entro dicembre'
"Il Testo unico sulla legislazione farmaceutica, che ha come obiettivo quello compendiare 800 fra...
08
Mag
Min. Salute Gemmato: “Testo unico farmaceutico entro dicembre 2026”
Il sottosegretario alla Salute indica la tabella di marcia della riforma. Al centro accesso ai farmaci...
08
Mag
Precursori droghe: controllo esteso a 9 nuove sostanze dal 18 settembre 2026
Regolamento delegato (UE) 2026/314 della Commissione del 9 febbraio 2026 recante modifica del regolamento...
le ultime news
11 Mar
PFAS restriction proposal: ECHA’s Socio-Economic Analysis Committee agrees its draft opinion
11 Mar
Farmaci - Gemmato: In cantiere anche un ritorno nazionale alla chimica farmaceutica di base
11 Mar
EMA outlines methods for evaluating supply chain vulnerabilities
09 Mar
US FDA drafts guidance on best practices for responding to inspection observations
09 Mar
Intelligenza Artificiale e salute: le agenzie regolatorie al centro della rivoluzione farmaceutica
06 Mar
Testo unico Legislazione Farmaceutica,: assegnato alla X Commissione Senato
04 Mar
ECHA’s Risk Assessment Committee adopts its opinion on PFAS restriction proposal
27 Feb
US FDA Announces the 2026 QMM Prototype Assessment Protocol Evaluation Program